Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Toxins (Basel). 2020 Feb 25;12(3):140. doi: 10.3390/toxins12030140.


Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.

Keywords: FGF23; PTH; chronic kidney disease; klotho; left ventricular hypertrophy; phosphate; sclerostin.; uremic cardiopathy.

Publication types

  • Review

MeSH terms

  • Animals
  • Avitaminosis / epidemiology
  • Avitaminosis / metabolism
  • Biomarkers / metabolism
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / metabolism*
  • Cardiovascular System
  • Chronic Kidney Disease-Mineral and Bone Disorder / epidemiology
  • Chronic Kidney Disease-Mineral and Bone Disorder / metabolism*
  • Comorbidity
  • Fibroblast Growth Factor-23
  • Humans
  • Parathyroid Hormone / metabolism
  • Phosphates / metabolism
  • Risk Factors


  • Biomarkers
  • FGF23 protein, human
  • Parathyroid Hormone
  • Phosphates
  • Fibroblast Growth Factor-23